Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945366 | 0.91 | KDM4E (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25446866 | 0.86 | — | — | |
| SCHEMBL23945631 | 0.79 | TSHR (0.33) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21106579 | 0.79 | CYP2C19 (0.37) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19676658 | 0.79 | HSD17B10 (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25826994 | 0.79 | CYP2C19 (0.37) | KDM4ECYP1A2CYP2C19 | |
| SCHEMBL23945337 | 0.78 | KDM4E (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21105961 | 0.78 | KDM4E (0.33) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL22861747 | 0.77 | SCN1A (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23340992 | 0.77 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CYP1A2 3570/4885CYP2D6 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.